Hypertension, Kidney and Pregnancy

高血压、肾脏和怀孕

基本信息

  • 批准号:
    8433334
  • 负责人:
  • 金额:
    $ 35.58万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-04-01 至 2015-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Pregnancy-induced hypertension or preeclampsia (PE) is estimated to affect 5-7% of all pregnancies in the U.S. Despite its position as a leading cause of maternal death and major contributor to maternal and perinatal morbidity, there is no effective drug treatment to prevent PE. At present, the only effective treatment for PE is early delivery. Based on recent studies and on preliminary data presented in this application, we propose that induction of the stress response gene, hemeoxygenase-1 (HO-1), and its catalytic products, carbon monoxide (CO) and bilirubin, may provide a novel therapeutic approach for the treatment of PE. There is mounting evidence that HO-1 and/or its catalytic products confer cytoprotection against cellular injury in response to placental ischemia, an important initiating event in the pathophysiology of PE. In fact, TNF1 mediated cellular damage in placental villous explants can be prevented by up-regulating HO activity. HO pathways have also been shown to inhibit the release of the anti-angiogenic factor, sFlt-1, in several in vitro models. Our preliminary data also indicates that chronic administration of an HO-1 enzyme inducer or a CO releasing molecule significantly attenuates hypertension in two well-established rat models of PE. Based on our preliminary data, we propose to test the central hypothesis that HO-1 and its metabolites, CO and bilirubin, attenuate the blood pressure and renal responses to placental ischemia in pregnant rats by inhibition of sFlt-l production. In addition, we propose that HO-1 derived products improve renal function and decrease total peripheral resistance and blood pressure by inhibiting the placental production of TNF1 and reactive oxygen species (ROS) and attenuating TNF1 and AT1 receptor autoantibody -induced increases in endothelial cell production of endothelin (ET-1). To test this hypothesis, arterial pressure, renal function, and endothelial factors will be examined in a conscious rat model of PE produced by long-term reductions in uterine perfusion pressure (RUPP). In addition to the RUPP model, a sFlt-1 model of PE will be used to determine the interaction between the HO-1 metabolites and sFlt-1, ET-1, and ROS production while in vitro placental explant and endothelial cell culture models will be used to examine the direct interaction of HO-metabolites in hypoxia- mediated induction of TNF, ROS and placental sFlt-1 and TNF induced ET-1 production. Specific aims are: 1) To test the hypothesis that HO-1 and its metabolites, CO and bilirubin, attenuate the blood pressure, renal, and sFlt-1 responses to placental ischemia in pregnant rats 2) To test the hypothesis that HO-1 and its metabolites, CO and bilirubin, attenuate placental ischemia and/or hypoxia-induced increases in reactive oxygen species and TNF1 3) To test the hypothesis that HO-1 and its metabolites, CO and bilirubin, attenuate TNF1 and AT1 receptor autoantibody- induced increases in ET-1 production 4) To test the hypothesis that the endogenous HO-1 pathway plays a role in regulating renal function and arterial pressure during normal pregnancy and in response to placental ischemia
描述(申请人提供):妊娠高血压综合征或先兆子痫(PE)在美国估计影响5%-7%的妊娠。尽管它是孕产妇死亡的主要原因和孕产妇和围产期发病率的主要贡献者,但没有有效的药物治疗来预防PE。目前,对PE唯一有效的治疗方法是早产。根据最近的研究和应用中的初步数据,我们认为诱导应激反应基因血红素加氧酶-1(HO-1)及其催化产物一氧化碳(CO)和胆红素可能为PE的治疗提供一种新的治疗途径。越来越多的证据表明,HO-1和/或其催化产物对胎盘缺血所致的细胞损伤具有细胞保护作用,这是PE病理生理过程中的一个重要启动事件。事实上,TNF1介导的胎盘绒毛外植体细胞损伤可以通过上调HO活性来防止。在几种体外模型中,HO通路也被证明可以抑制抗血管生成因子sFlt-1的释放。我们的初步数据还表明,长期服用HO-1酶诱导剂或CO释放分子可显著降低两种已建立的PE大鼠模型的高血压。根据我们的初步数据,我们建议检验HO-1及其代谢物CO和胆红素,通过抑制sFlt-L的产生来减轻妊娠大鼠对胎盘缺血的血压和肾脏反应的中心假设。此外,我们认为,HO-1衍生产品可通过抑制胎盘组织中TNF1和ROS的产生,以及减轻TNF1和AT1受体自身抗体诱导的内皮细胞分泌内皮素(ET-1)的增加,从而改善肾功能,降低外周阻力和血压。为了验证这一假设,将在长期降低子宫灌注压(RUPP)所产生的PE的清醒大鼠模型中检测动脉压、肾功能和内皮因子。除了RUPP模型外,还将使用PE的sFlt-1模型来确定HO-1代谢产物与sFlt-1、ET-1和ROS的产生之间的相互作用,而在体外胎盘组织和内皮细胞培养模型中,将研究HO-代谢物在低氧诱导的TNF、ROS和胎盘sFlt-1和TNF诱导的ET-1产生中的直接相互作用。具体目的是:1)检验HO-1及其代谢产物CO和胆红素减弱妊娠大鼠对胎盘缺血的血压、肾脏和sFlt-1反应的假设2)检验HO-1及其代谢产物CO和胆红素减轻胎盘缺血和/或缺氧诱导的活性氧和TNF1增加的假说3)检验HO-1及其代谢产物CO和胆红素,减弱TNF1和AT1受体自身抗体诱导的ET-1生成增加4)验证内源性HO-1途径在正常妊娠期间和胎盘缺血反应中调节肾功能和动脉压的假设

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joey P. Granger其他文献

Intrauterine endotoxin infusion in rat pregnancy induces preterm delivery and increases placental prostaglandin F2alpha metabolite levels.
大鼠妊娠宫内输注内毒素可诱导早产并增加胎盘前列腺素 F2α 代谢水平。
  • DOI:
  • 发表时间:
    2000
  • 期刊:
  • 影响因子:
    9.8
  • 作者:
    William A. Bennett;D. Terrone;B. K. Rinehart;Sallah Kassab;James N. Martin;Joey P. Granger
  • 通讯作者:
    Joey P. Granger
[18-OR]: Enhanced angiogenic balance and vasorelaxation during pregnancy in obese MC4R-deficient rats
  • DOI:
    10.1016/j.preghy.2014.10.022
  • 发表时间:
    2015-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Frank T. Spradley;Ana C. Palei;Joey P. Granger
  • 通讯作者:
    Joey P. Granger
A new genetic clue to unravel the origins of pre-eclampsia
解开子痫前期起源的新遗传线索
  • DOI:
    10.1038/nrneph.2017.116
  • 发表时间:
    2017-09-04
  • 期刊:
  • 影响因子:
    39.800
  • 作者:
    Eric M. George;Joey P. Granger
  • 通讯作者:
    Joey P. Granger
[13-OR]: Role of nitric oxide on blood pressure regulation in pregnant rats on a high-fat diet (HFD)
  • DOI:
    10.1016/j.preghy.2014.10.017
  • 发表时间:
    2015-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Ana C. Palei;Frank T. Spradley;Joey P. Granger
  • 通讯作者:
    Joey P. Granger
[279-POS]: Potential therapeutic value of the heme oxygenase system in preeclampsia
  • DOI:
    10.1016/j.preghy.2014.10.285
  • 发表时间:
    2015-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Eric M. George;Joey P. Granger
  • 通讯作者:
    Joey P. Granger

Joey P. Granger的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joey P. Granger', 18)}}的其他基金

Administrative Core
行政核心
  • 批准号:
    10281516
  • 财政年份:
    2016
  • 资助金额:
    $ 35.58万
  • 项目类别:
Mississippi Center for Clinical and Translational Research
密西西比临床和转化研究中心
  • 批准号:
    10472628
  • 财政年份:
    2016
  • 资助金额:
    $ 35.58万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10472630
  • 财政年份:
    2016
  • 资助金额:
    $ 35.58万
  • 项目类别:
Mississippi Center for Clinical and Translational Research
密西西比临床和转化研究中心
  • 批准号:
    10281515
  • 财政年份:
    2016
  • 资助金额:
    $ 35.58万
  • 项目类别:
MCCTR/UMMC Year4 N3C Grant Initiative
MCCTR/UMMC Year4 N3C 资助计划
  • 批准号:
    10887860
  • 财政年份:
    2016
  • 资助金额:
    $ 35.58万
  • 项目类别:
International Society for the Study of Hypertension in Pregnancy (ISSHP) World Congress
国际妊娠期高血压研究学会 (ISSHP) 世界大会
  • 批准号:
    8838489
  • 财政年份:
    2014
  • 资助金额:
    $ 35.58万
  • 项目类别:
Preeclampsia, IUGR and Hypertension: Targets for Treatment
先兆子痫、IUGR 和高血压:治疗目标
  • 批准号:
    8518448
  • 财政年份:
    2012
  • 资助金额:
    $ 35.58万
  • 项目类别:
Preeclampsia, IUGR and Hypertension: Targets for Treatment
先兆子痫、IUGR 和高血压:治疗目标
  • 批准号:
    8385761
  • 财政年份:
    2012
  • 资助金额:
    $ 35.58万
  • 项目类别:
Hypertension, Kidney and Pregnancy
高血压、肾脏和怀孕
  • 批准号:
    8247752
  • 财政年份:
    2011
  • 资助金额:
    $ 35.58万
  • 项目类别:
Hypertension, Kidney and Pregnancy
高血压、肾脏和怀孕
  • 批准号:
    8601899
  • 财政年份:
    2011
  • 资助金额:
    $ 35.58万
  • 项目类别:

相似海外基金

How angiogenic factor induces immunosuppressive cells to tumor microenvironment
血管生成因子如何诱导免疫抑制细胞进入肿瘤微环境
  • 批准号:
    22KJ0818
  • 财政年份:
    2023
  • 资助金额:
    $ 35.58万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Validation of Adenylosuccinate as a Novel Endogenous Pro-Angiogenic Factor in the Brain
腺苷琥珀酸作为大脑中新型内源性促血管生成因子的验证
  • 批准号:
    10711027
  • 财政年份:
    2021
  • 资助金额:
    $ 35.58万
  • 项目类别:
Validation of Adenylosuccinate as a Novel Endogenous Pro-Angiogenic Factor in the Brain
腺苷琥珀酸作为大脑中新型内源性促血管生成因子的验证
  • 批准号:
    10297199
  • 财政年份:
    2021
  • 资助金额:
    $ 35.58万
  • 项目类别:
Validation of Adenylosuccinate as a Novel Endogenous Pro-Angiogenic Factor in the Brain
腺苷琥珀酸作为大脑中新型内源性促血管生成因子的验证
  • 批准号:
    10625314
  • 财政年份:
    2021
  • 资助金额:
    $ 35.58万
  • 项目类别:
Validation of Adenylosuccinate as a Novel Endogenous Pro-Angiogenic Factor in the Brain
腺苷琥珀酸作为大脑中新型内源性促血管生成因子的验证
  • 批准号:
    10405070
  • 财政年份:
    2021
  • 资助金额:
    $ 35.58万
  • 项目类别:
Physiological role of anti-angiogenic factor thrombospondin in the regulation of endometrial function during early pregnancy in cattle
抗血管生成因子血小板反应蛋白在牛妊娠早期子宫内膜功能调节中的生理作用
  • 批准号:
    20K06385
  • 财政年份:
    2020
  • 资助金额:
    $ 35.58万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Elucidation of lymphangiogenic regulatory mechanism of angiogenic factor CCN2 through tumor-associated macrophage
阐明血管生成因子CCN2通过肿瘤相关巨噬细胞的淋巴管生成调节机制
  • 批准号:
    17K11866
  • 财政年份:
    2017
  • 资助金额:
    $ 35.58万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Elucidation of vascular stabilization mechanism by anti-angiogenic factor vasohibin-1
抗血管生成因子 vasohibin-1 阐明血管稳定机制
  • 批准号:
    15K20874
  • 财政年份:
    2015
  • 资助金额:
    $ 35.58万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
angiogenic therapy for cerebral infarction with anti^sense homology derived peptide targeting angiogenic factor
靶向血管生成因子的反义同源肽治疗脑梗死
  • 批准号:
    15K15523
  • 财政年份:
    2015
  • 资助金额:
    $ 35.58万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
The development of the anti-angiogenic factor VEGF-A165b quantification methods for cardiovascular disease.
心血管疾病抗血管生成因子 VEGF-A165b 定量方法的开发。
  • 批准号:
    26860367
  • 财政年份:
    2014
  • 资助金额:
    $ 35.58万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了